Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026)

Vertex Pharmaceuticals' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 1031400000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 59.59% year-over-year to 1031400000.0 in Q1 2026; TTM through Mar 2026 was 4338300000.0, a 538.7% increase from a year earlier, with the FY2025 full-year figure at 3953200000.0, up 838.09% from the prior year.
• Income from Continuing Operations eased to 1031400000.0 in Q1 2026 per VRTX's latest filing, from 1191100000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 1191100000.0 in Q4 2025 and bottomed at 3593600000.0 in Q2 2024.
• The 5-year median for Income from Continuing Operations is 930500000.0 (2022), against an average of 670035294.12.
• Across the five-year window, Income from Continuing Operations soared 1109.7% in 2022 and tumbled 492.44% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 818900000.0 in 2022, then grew by 18.31% to 968800000.0 in 2023, then decreased by 5.76% to 913000000.0 in 2024, then jumped by 30.46% to 1191100000.0 in 2025, then decreased by 13.41% to 1031400000.0 in 2026.
• Per Business Quant, the three latest VRTX Income from Continuing Operations figures stand at 1031400000.0 (Q1 2026), 1191100000.0 (Q4 2025), and 1082900000.0 (Q3 2025).